Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116225 | 0.89 | SMN1; SMN2 (0.41) | HSD11B1SMN1; SMN2HTR4USP7USP30 | |
| SCHEMBL20116787 | 0.87 | SMN1; SMN2 (0.45) | HSD11B1SMN1; SMN2HTR4RAB9AUSP7 | |
| SCHEMBL20116073 | 0.86 | SMN1; SMN2 (0.41) | HSD11B1SMN1; SMN2HTR4USP7USP30 | |
| SCHEMBL20116077 | 0.85 | SMN1; SMN2 (0.39) | HSD11B1SMN1; SMN2HTR4USP7USP30 | |
| SCHEMBL22357857 | 0.85 | HSD11B1 (0.54) | HSD11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20116783 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2HTR4USP7EGLN1USP30 | |
| SCHEMBL20116456 | 0.85 | GBA1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL20116228 | 0.85 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2TP53UBE2MDCUN1D1 | |
| SCHEMBL20116779 | 0.84 | RAB9A (0.44) | HSD11B1SMN1; SMN2UBE2MDCUN1D1RAB9A | |
| SCHEMBL20116506 | 0.83 | SMO (0.42) | SMN1; SMN2HTR4RAB9AUSP7USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HSD11B1 1676/4885SMN1; SMN2 13/4885HTR4 482/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | HSD11B1 1676/4885SMN1; SMN2 13/4885HTR4 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.